These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 32605647)

  • 1. Analytical evaluation of the clonoSEQ Assay for establishing measurable (minimal) residual disease in acute lymphoblastic leukemia, chronic lymphocytic leukemia, and multiple myeloma.
    Ching T; Duncan ME; Newman-Eerkes T; McWhorter MME; Tracy JM; Steen MS; Brown RP; Venkatasubbarao S; Akers NK; Vignali M; Moorhead ME; Watson D; Emerson RO; Mann TP; Cimler BM; Swatkowski PL; Kirsch IR; Sang C; Robins HS; Howie B; Sherwood A
    BMC Cancer; 2020 Jun; 20(1):612. PubMed ID: 32605647
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multiparameter flow cytometry and ClonoSEQ correlation to evaluate precursor B-lymphoblastic leukemia measurable residual disease.
    Momen N; Tario J; Fu K; Qian YW
    J Hematop; 2023 Jun; 16(2):85-94. PubMed ID: 38175444
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Minimal residual disease detection by next-generation sequencing of different immunoglobulin gene rearrangements in pediatric B-ALL.
    Chen H; Gu M; Liang J; Song H; Zhang J; Xu W; Zhao F; Shen D; Shen H; Liao C; Tang Y; Xu X
    Nat Commun; 2023 Nov; 14(1):7468. PubMed ID: 37978187
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Concordance of Next-Generation Sequencing and Multiparametric Flow Cytometry Methods for Detecting Measurable Residual Disease in Adult Acute Lymphoblastic Leukemia: Optimizing Prediction of Clinical Outcomes From a Single-Center Study.
    Ashouri K; Nittur V; Ginosyan AA; Hwang J; Adnani B; Chen D; Savitala-Damerla L; Schiff K; Chaudhary P; Kovach AE; Ladha A; Siddiqi I; Ali A; Woan K; Tam E; Yaghmour G
    Clin Lymphoma Myeloma Leuk; 2024 Mar; 24(3):e59-e66.e2. PubMed ID: 38061959
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of Measurable Residual Disease in Pediatric B-Lymphoblastic Leukemia Using Multiparametric Flow Cytometry and Next-Generation Sequencing.
    Hwang SM; Oh I; Kwon SR; Lee JS; Seong MW
    Ann Lab Med; 2024 Jul; 44(4):354-358. PubMed ID: 38237930
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantification of Measurable Residual Disease Detection by Next-Generation Sequencing-Based Clonality Testing in B-Cell and Plasma Cell Neoplasms.
    Liu Y; Ho C; Yu W; Huang Y; Miller J; Gao Q; Syed M; Ma Y; Wang M; Maciag L; Petrova-Drus K; Zhu M; Yao J; Vanderbilt C; Durham B; Benhamida J; Ewalt MD; Dogan A; Roshal M; Nafa K; Arcila ME
    J Mol Diagn; 2024 Mar; 26(3):168-178. PubMed ID: 38103591
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Performance of a novel eight-color flow cytometry panel for measurable residual disease assessment of chronic lymphocytic leukemia.
    Chen X; Chen X; Zhao S; Shi Y; Zhang N; Guo Z; Qiao C; Jin H; Zhu L; Zhu H; Li J; Wu Y
    Cytometry B Clin Cytom; 2024 May; 106(3):181-191. PubMed ID: 38535092
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analytical assay validation for acute myeloid leukemia measurable residual disease assessment by multiparametric flow cytometry.
    Tettero JM; Dakappagari N; Heidinga ME; Oussoren-Brockhoff Y; Hanekamp D; Pahuja A; Burns K; Kaur P; Alfonso Z; van der Velden VHJ; Te Marvelde JG; Hobo W; Slomp J; Bachas C; Kelder A; Nguyen K; Cloos J
    Cytometry B Clin Cytom; 2023 Nov; 104(6):426-439. PubMed ID: 37766649
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NGS better discriminates true MRD positivity for the risk stratification of childhood ALL treated on an MRD-based protocol.
    Svaton M; Skotnicova A; Reznickova L; Rennerova A; Valova T; Kotrova M; van der Velden VHJ; Brüggemann M; Darzentas N; Langerak AW; Zuna J; Stary J; Trka J; Fronkova E
    Blood; 2023 Feb; 141(5):529-533. PubMed ID: 36240445
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clonotypic VDJ Rearrangements in Mixed Phenotype Acute Leukemia can be Successfully Utilized to Track Minimal Residual Disease.
    Hennawi M; Quadeer F; Pakasticali N; Osman S; Tashkandi H; Hussaini MO
    Appl Immunohistochem Mol Morphol; 2024 Aug; 32(7):305-308. PubMed ID: 38695552
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Measurable residual disease testing by next generation sequencing is more accurate compared with multiparameter flow cytometry in adults with B-cell acute lymphoblastic leukemia.
    Yan N; Wang ZL; Wang XJ; Gale RP; Zhou YL; Zhao MY; Wu LX; Liao MY; Yang J; Wang CY; Zhu JH; Jiang H; Jiang Q; Liu YR; Chang YJ; Xu LP; Zhang XH; Ma TH; Huang XJ; Ruan GR
    Cancer Lett; 2024 Aug; 598():217104. PubMed ID: 38969163
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Minimal Residual Disease Detection in Acute Lymphoblastic Leukemia.
    Kruse A; Abdel-Azim N; Kim HN; Ruan Y; Phan V; Ogana H; Wang W; Lee R; Gang EJ; Khazal S; Kim YM
    Int J Mol Sci; 2020 Feb; 21(3):. PubMed ID: 32033444
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genomic breakpoint-specific monitoring of measurable residual disease in pediatric non-standard-risk acute myeloid leukemia.
    Maurer-Granofszky M; Kohrer S; Fischer S; Schumich A; Nebral K; Larghero P; Meyer C; Mecklenbrauker A; Muhlegger N; Marschalek R; Haas OA; Panzer-Grumayer R; Dworzak MN
    Haematologica; 2024 Mar; 109(3):740-750. PubMed ID: 37345487
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Highly sensitive single tube B-lymphoblastic leukemia/lymphoma minimal/measurable residual disease test robust to surface antigen directed therapy.
    Gao Q; Liu Y; Aypar U; Baik J; Londono D; Sun X; Zhang J; Zhang Y; Roshal M
    Cytometry B Clin Cytom; 2023 Jul; 104(4):279-293. PubMed ID: 36999235
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunoglobulin High Throughput Sequencing (Ig-HTS) Minimal Residual Disease (MRD) Analysis is an Effective Surveillance Tool in Patients With Mantle Cell Lymphoma.
    Rezazadeh A; Pruett J; Detzner A; Edwin N; Hamadani M; Shah NN; Fenske TS
    Clin Lymphoma Myeloma Leuk; 2024 Apr; 24(4):254-259. PubMed ID: 38195321
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Automated quantification of measurable residual disease in chronic lymphocytic leukemia using an artificial intelligence-assisted workflow.
    Bazinet A; Wang A; Li X; Jia F; Mo H; Wang W; Wang SA
    Cytometry B Clin Cytom; 2024 Jul; 106(4):264-271. PubMed ID: 36824056
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Defining the undetectable: The current landscape of minimal residual disease assessment in multiple myeloma and goals for future clarity.
    Diamond BT; Rustad E; Maclachlan K; Thoren K; Ho C; Roshal M; Ulaner GA; Landgren CO
    Blood Rev; 2021 Mar; 46():100732. PubMed ID: 32771227
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IGH translocations in chronic lymphocytic leukemia: Clinicopathologic features and clinical outcomes.
    Fang H; Reichard KK; Rabe KG; Hanson CA; Call TG; Ding W; Kenderian SS; Muchtar E; Schwager SM; Leis JF; Chanan-Khan AA; Slager SL; Braggio E; Smoley SA; Kay NE; Shanafelt TD; Van Dyke DL; Parikh SA
    Am J Hematol; 2019 Mar; 94(3):338-345. PubMed ID: 30575108
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of next-generation sequencing versus next-generation flow cytometry for minimal-residual-disease detection in Chinese patients with multiple myeloma.
    Zhou M; Chen Y; Gong Y; Zhu M; Cen J; Pan J; Yan L; Shang J; Jin S; Shi X; Yao W; Yan S; Wu D; Chen S; Fu C; Yao L
    Discov Oncol; 2024 Mar; 15(1):78. PubMed ID: 38502423
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The kappa/lambda ratio of surface immunoglobulin light chain as a valuable parameter for MRD assessment in CLL with atypical immunophenotype.
    Aruga Y; Ikeda C; Matsushita H; Makita S; Fukuhara S; Munakata W; Izutsu K; Matsui H
    Sci Rep; 2024 Jun; 14(1):13452. PubMed ID: 38862612
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.